



## Progress on Seasonal and Pandemic Influenza Vaccines

Guest Editors:

**Prof. Emanuele Montomoli**

Department of Molecular and  
Developmental Medicine,  
Università degli Studi di Siena,  
Siena, Italy

**Dr. Claudia Maria Trombetta**

Department of Molecular and  
Developmental Medicine,  
University of Siena, Banchi di  
Sotto, 55, 53100 Siena, SI, Italy

Deadline for manuscript  
submissions:

**closed (31 May 2021)**

### Message from the Guest Editors

Dear Colleagues,

Vaccination is the most effective method of controlling seasonal influenza infections and preventing possible pandemic events. To date, three different classes of influenza vaccines have been licensed: inactivated, live attenuated and recombinant haemagglutinin vaccines. Most of the current influenza vaccines are still produced and/or isolated in hen's eggs; however, several novel platforms and technologies are being developed for the production of the next-generation vaccines.

This special issue focuses on recent progress on seasonal and pandemic influenza vaccines. The goal is to provide an overview of different types of influenza vaccine, new technologies and platforms under development for the next-generation vaccines.

This special issue invites contribution to these topics.

Prof. Emanuele Montomoli

Dr. Claudia Trombetta

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)